In August 2025 it received accelerated FDA approval for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, becoming the first GLP-1 receptor agonist approved for MASH, alongside resmetirom as the only approved therapies for this indication, on the basis of the Phase 3 ESSENCE trial in which resolution of steatohepatitis without worsening of fibrosis was achieved in 63% of patients on semaglutide versus 34% on placebo at week 72
[DOI] [PubMed] [Google Scholar] 4.Wu C., Targher G., Byrne C.D., Mao Y., Cheung T.T., Yilmaz Y., Valenti L., Mndez-Snchez N., Sookoian S., Chan W.K., et al
There is no generic semaglutide, so any provider marketing generic Ozempic or generic Wegovy is making a false claim, which is a hard red flag
Storage Conditions : Store at 20C, protected from light and moisture